Orion OYJ (OTCMKTS:ORINY) Downgraded to "Hold" Rating by Zacks Research

Key Points

• Zacks Research has downgraded Orion OYJ from a "strong-buy" rating to a "hold" rating, indicating a shift in confidence among analysts.
• Orion OYJ reported a quarterly earnings of $0.33 per share on revenue of $472.57 million, with a net margin of 22.61%.
• The company's shares opened at $38.95, reflecting its recent performance within a 52-week range of $21.95 to $41.60.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued on Monday, September 8th,Zacks.com reports.

Orion OYJ Price Performance

Shares of OTCMKTS ORINY remained flat at $38.95 during mid-day trading on Monday. The company had a trading volume of 48 shares, compared to its average volume of 250. The company has a current ratio of 1.86, a quick ratio of 1.05 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $10.99 billion, a PE ratio of 26.50 and a beta of 0.11. Orion OYJ has a 1 year low of $21.95 and a 1 year high of $41.60. The business has a 50-day simple moving average of $39.47 and a 200-day simple moving average of $34.45.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last issued its quarterly earnings data on Friday, July 18th. The company reported $0.33 earnings per share for the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%.The firm had revenue of $472.57 million during the quarter. On average, equities analysts forecast that Orion OYJ will post 1.18 earnings per share for the current year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.